M
Mariana Puntel
Researcher at Cedars-Sinai Medical Center
Publications - 39
Citations - 1816
Mariana Puntel is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Genetic enhancement & Glioma. The author has an hindex of 25, co-authored 39 publications receiving 1691 citations. Previous affiliations of Mariana Puntel include University of California & University of Michigan.
Papers
More filters
Journal ArticleDOI
Regulatable Gene Expression Systems for Gene Therapy Applications: Progress and Future Challenges
Shyam Goverdhana,Mariana Puntel,Weidong Xiong,Jeffrey M. Zirger,Carlos Barcia,James F. Curtin,E. B. Soffer,Sonali Mondkar,Gwendalyn D. King,Jiang Hu,Sandra A. Sciascia,Marianela Candolfi,Diana S. Greengold,Pedro R. Lowenstein,Maria G. Castro +14 more
TL;DR: The main regulatable systems currently under development, the gene transfer systems employed for their expression, and also the preclinical models in which they have been used successfully are highlighted and the substantial challenges that still remain are discussed.
Journal ArticleDOI
Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model
Sumia Ali,Gwendalyn D. King,James F. Curtin,Marianela Candolfi,Weidong Xiong,Chunyan Liu,Mariana Puntel,Queng Cheng,Jesús Prieto,Antoni Ribas,Jerzy W. Kupiec-Weglinski,Nico van Rooijen,Hans Lassmann,Pedro R. Lowenstein,Pedro R. Lowenstein,Maria G. Castro,Maria G. Castro +16 more
TL;DR: It is proposed that combined Flt3L and HSV1-TK adenoviral-mediated gene therapy may provide an effective antiglioma treatment with increased efficacy in clinical trials of glioma.
Journal ArticleDOI
Gene Therapy and Targeted Toxins for Glioma
Maria G. Castro,Marianela Candolfi,Kurt M. Kroeger,Gwendalyn D. King,James F. Curtin,Kader Yagiz,Yohei Mineharu,Hikmat Assi,Mia Wibowo,A.K.M. Ghulam Muhammad,David Foulad,Mariana Puntel,Pedro R. Lowenstein +12 more
TL;DR: This review will examine the available preclinical models for glioma including xenographs, syngeneic and genetic models to determine which strategies will provide rapid tumor regression and long-term protection from recurrence.
Journal ArticleDOI
Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.
Marianela Candolfi,Kader Yagiz,David Foulad,Gabrielle E. Alzadeh,Matthew Tesarfreund,A.K.M. Ghulam Muhammad,Mariana Puntel,Kurt M. Kroeger,Chunyan Liu,Sharon Lee,James F. Curtin,Gwendalyn D. King,Jonathan Lerner,Katsuaki Sato,Yohei Mineharu,Weidong Xiong,Pedro R. Lowenstein,Maria G. Castro +17 more
TL;DR: The results indicate that Ad-TK+GCV+Ad-Flt3L exhibit the highest efficacy and safety profile among the several proapoptotic approaches tested.
Journal ArticleDOI
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics
Marianela Candolfi,Weidong Xiong,Kader Yagiz,Chunyan Liu,Akm Ghulam Muhammad,Mariana Puntel,David Foulad,Ali Zadmehr,Gabrielle E. Ahlzadeh,Kurt M. Kroeger,Matthew Tesarfreund,Sharon Lee,Waldemar Debinski,Dhruv Sareen,Clive N. Svendsen,Ronald Rodriguez,Pedro R. Lowenstein,Maria G. Castro +17 more
TL;DR: A regulatable adenoviral vector encoding a mutated human IL-13 fused to Pseudomonas exotoxin that specifically binds to IL13Rα2 to provide sustained expression, effective anti-GBM cytotoxicity, and minimal neurotoxicity is developed, representing a significant advance in the development of targeted therapeutics for GBM.